DRUG UTILIZATION EVALUATION AND COST ANALYSIS OF ANTIEMETIC DRUGS PRESCRIBED IN ONCOLOGY WARD IN A QUATERNARY CARE HOSPITAL
DOI:
https://doi.org/10.22159/ajpcr.2016.v9i5.12464Abstract
Objective: Drug utilization is defined by the World Health Organization as the marketing, distribution, prescription, and use of drugs in society, with
special emphasis on the resulting medical, social, and economic consequences. Our study is done to obtain the variation of drug use and costs of drug therapy, from which medical and social qualitative consequences can be found. Our study emphasizes on knowing the drug utilization and cost
included for antiemetics in patients undergoing chemotherapy in oncology ward.
Methods: It was observational, prospective and non-interventional study.
Results: Total of 141 patients were studied, out of which 77 (54.6%) patients were female and 64 (45.4%) patients were males. The majority of the
patients in this study belong to the age group of 40-49 (29%) and 60-69 (20%) years. The comparison with the standard protocol was made according
to the use of antiemetics in the patients. Out of which, 137 (97%) patient profiles were found to be deviating from standard protocol, and 4 (3%)
patient profiles were found following the standard protocol because of including prochlorperazine which is not mentioned in the standard protocol.
Conclusion: As of future approach, education to physician for rational drug use and review of medication chart with patient consideration can give
better health care and also cost effective treatment.
Keywords: Drug use evaluation, Antiemetics, Chemotherapy.
Downloads
References
Biomed. Appraisal of Guidelines for Research and Evaluation in Europe (AGREE) Instrument. 2nd Draft, BIOMED Project PL96-3669; 2000.
Truter I. A review of drug utilization studies and methodologies. Jordan J Pharm Sci 2008;1(2):91-104.
ASHP. Best Practices for Health-System Pharmacy: Positions and Practice Standards. Bethesda, MD: American Society for Health-System Pharmacists; 1999-2000.
Fulda TR, Lyles A, Pugh MC, Dale B. Current status of prospective drug utilization review. J Manage Care Pharm 2004;10(5):433-41.
Raveh D, Muallem-Zilcha E, Greenberg A, Wiener-Well Y, Schlesinger Y, Yinnon AM. Prospective drug utilization evaluation of three broad-spectrum antimicrobials: Cefepime, piperacillin-tazobactam and meropenem. QJM 2006;99:397-406.
Kulkarni MD, Hussaini SA, Padwal SL, Khandelwal PN, Doifode SM, More P. Drug utilization review of anticancer drugs in cancer outpatient department of the Government Medical College, Aurangabad. Int J Basic Clin Pharmacol 2014;3(5):879-83.
Siddiqua A, Jfar H, Tabassum N, Firdous S, Tabassum K. Drug utilization evaluation of anticancer drugs. Am J PharmTech Res 2014;4(3):690-702.
Cheekavolu C, Pathapati RM, Babasaheb Laxmansingh K, Saginela SK, Makineedi VP, Siddalingappa, et al. Evaluation of drug utilization patterns during initial treatment in the emergency room: A retroprospective pharmacoepidemiological Study. ISRN Pharmacol 2011;2011:261585.
Truter I, Kotze TJ. A drug utilisation study investigating prescribed daily doses ofhypolipidaemic agents: S Afr Med J 1996;86(11):1397-401.
Robinson R. Cost-effectiveness analysis. BMJ 1993;307:793-5.
Lutchman D. Pharmacoeconomics and the clinician: A South African perspective. S Afr Fam Pract 2011;53:92.
Warr DG, Hesketh PJ, Gralla RJ, Muss HB, Herrstedt J, Eisenberg PD, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 2005;23:2822-30.
Gündüz E, Gülbas Z. Supportive care in hemato-oncology: A review in light of the latest guidelines. Turk J Haematol 2012;29:1-9.
Navari MR. Overview of the updated antiemetic guidelines for chemotherapy-induced nausea and vomiting. Commun Oncol 2007;4 Suppl 1:3-11.
Ondansetron versus metoclopramide, both combined with dexamethasone, in the prevention of cisplatin-induced delayed emesis. The Italian Group for Antiemetic Research. J Clin Oncol 1997;15:124-30.
Donnerer J, editor. The emetic reflex arc. Antimetic Therapy. Basel, Switzerland: S. Karger AG; 2003. p. 1-10.
Berger AM, Clark-Snow RA. In: Cancer: Principles and Practice of Oncology. Philadelphia, PA: Lippincott Williams & Wilkins; 2001.
Schnell FM. Chemotherapy-induced nausea and vomiting: The importance of acute antiemetic control. Oncologist 2003;8:187-98.
Samilski JA, Lau TT, Elbe DH, Aulakh AK, Lun EM. Drug use evaluation of moxifloxacin (avelox) using a hand-held electronic device at a canadian teaching hospital. P T 2012;37:291-9.
Doherty KM. Closing the gap in prophylactic antiemetic therapy: Patient factors in calculating the emetogenic potential of chemotherapy. Clin J Oncol Nurs 1999;3:113-9.
Plosker GL, Milne RJ. Ondansetron: A pharmacoeconomic and quality-of-life evaluation of its antiemetic activity in patients receiving cancer chemotherapy. Pharmacoeconomics 1992;2:285-304.
Weeks JC. Special issues that arise in applying techniques of economic analysis to evaluation of cancer therapies. Monogr Nat Inst1995;19:11-2.
Aapro MS. Costs and benefits of antiemetic therapy. Support Care Cancer 1994;2:304-6.
DeVane CL. Substance P: A new era, a new role. Pharmacotherapy 2001;21:1061-9.
Hargreaves R. Imaging substance P receptors (NK1) in the living human brain using positron emission tomography. J Clin Psychiatry 2002;63 Suppl 11:18-24.
Saria A. The tachykinin NK1 receptor in the brain: Pharmacology and putative functions. Eur J Pharmacol 1999;375(1-3):51-60.
Hesketh PJ. Potential role of the NK1 receptor antagonists in chemotherapy-induced nausea and vomiting. Support Care Cancer 2001;9:350-4.
Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: A multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin – The Aprepitant Protocol 052 Study Group. J Clin Oncol 2003;21:4112-9.
Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Julie Ma G, Eldridge K, Hipple A, et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 2003;97:3090-8.
Schmoll HJ, Aapro MS, Poli-Bigelli S, Kim HK, Park K, Jordan K, et al. Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Ann Oncol 2006;17:1000-6.
Jordan K, Hinke A, Grothey A, Voigt W, Arnold D, Wolf HH, et al. A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis. Support Care Cancer 2007;15(9):1023-33.
Roila F, Herrstedt J, Aapro M, Gralla RJ, Einhorn LH, Ballatori E, et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: Results of the Perugia consensus conference. Ann Oncol 2010;21 Suppl 5:v232-43.
NCCN Guidelines Version 1.2012. Antiemesis. National Comprehensive Cancer Network.
Jordan K, Sippel C, Schmoll HJ. Guidelines for antiemetic treatment of chemotherapy-induced nausea and vomiting: Past, present, and future recommendations. Oncologist 2007;12:1143-50.
Kris MG, Gralla RJ, Tyson LB, Clark RA, Cirrincione C, Groshen S. Controlling delayed vomiting: Double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin. J Clin Oncol 1989;7:108-14.
Gralla RJ, Osoba D, Kris MG, Kirkbride P, Hesketh PJ, Chinnery LW, et al. Recommendations for the use of antiemetics: Evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol 1999;17:2971-94.
Grunberg SM, Gala KV, Lampenfeld M, Jamin D, Johnson K, Cariffe P, et al. Comparison of the antiemetic effect of high-dose intravenous metoclopramide and high-dose intravenous haloperidol in a randomized double-blind crossover study. J Clin Oncol 1984;2:782-7.
Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med 2008;358:2482-94.
American Society of Clinical Oncology, Kris MG, Hesketh PJ, Somerfield MR, Feyer P, Clark-Snow R, et al. American Society of Clinical Oncology guideline for antiemetics in oncology: Update 2006. J Clin Oncol 2006;24:2932-47.
Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996;14:87-96.
Basch E, Prestrud AA, Hesketh PJ, Kris MG, Feyer PC, Somerfield MR, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2011;29:4189-98.
Yu S, Burke TA, Chan A, Kim HK, Hsieh RK, Hu X, et al. Antiemetic therapy in Asia Pacific countries for patients receiving moderately and highly emetogenic chemotherapy – A descriptive analysis of practice patterns, antiemetic quality of care, and use of antiemetic guidelines. Support Care Cancer 2015;23:273-82.
Rosso R, Campora E, Cetto G, Fosser V, Marangolo M, Oliva C. Oral ondansetron (GR38032F) for the control of acute and delayed cyclophosphamide-induced emesis. Anticancer Res 1991;11(2):937-9.
Aapro MS, Thuer2limann B, Sessa C, De Pree C, Bernhard J, Maibach R; Swiss Group for Clinical Cancer Research. A randomized double-blind trial to compare the clinical efficacy of granisetron with metoclopramide, both combined with dexamethasone in the prophylaxis of chemotherapy-induced delayed emesis. Ann Oncol 2003;14:291-7.
Hesketh PJ, Crews JR, Cohen R, Blackburn LM, Friedman CJ. Antiemetic efficacy of single-dose oral granisetron (1 mg vs 2 mg) with moderately emetogenic chemotherapy. Cancer J 2000;6:157-61.
Endo J, Iihara H, Yamada M, Yanase K, Kamiya F, Ito F, et al. A randomized controlled non-inferiority study comparing the antiemetic effect between intravenous granisetron and oral azasetron based on estimated 5-HT3 receptor occupancy. Anticancer Res 2012;32:3939-47.
Roila F, Tonato M, Del Favero A. Treatment of moderately emetogenic chemotherapy- induced nausea and vomiting. In: Dicato M, editor. Medical Management of Cancer Treatment Induced Emesis. London, UK: Martin Dunitz Ltd.; 1998. p. 87-101.
Friedman CJ, Burris HA 3rd, Yocom K, Blackburn LM, Gruben D. Oral granisetron for the prevention of acute late onset nausea and vomiting in patients treated with moderately emetogenic chemotherapy. Oncologist 2000;5(2):136-43.
Bubalo JS, Leis JF, Curin PT, Kovascovics TJ, Meyers G, Hayes-Lattin B, et al. A double blinded pilot study of aprepitant vs placebo combined with standard antiemetics for the control of nausea and vomiting during hematopoietic cell transplantation. Biol Blood Marrow Transplant 2007;13:152.
Bubalo JS, Leis JF, Curtin PT, Maziarz RT, Kovascovics TJ, Meyers G, et al. A randomized, double-blinded, pilot trial of aprepitant added to standard antiemetics during conditioning therapy for hematopoietic stem cell transplant (HSCT). J Clin Oncol 2007;25(18S):9112.
Jordan K, Jahn F, Jahn P, Behlendorf T, Stein A, Ruessel J, et al. The NK-1 receptor-antagonist aprepitant in high-dose chemotherapy (highdosemelphalan and high-dose T-ICE: Paclitaxel, ifosfamide, carboplatin, etoposide): Efficacy and safety of a triple antiemetic combination. Bone Marrow Transplant 2011;46(6):784-9.
Gralla RJ, Navari RM, Hesketh PJ, Popovic W, Strupp J, Noy J, et al. Single-dose oral granisetron has equivalent antiemetic efficacy to intravenous ondansetron for highly emetogenic cisplatin-based chemotherapy. J Clin Oncol 1998;16(4):1568-73.
Perez EA, Hesketh P, Sandbach J, Reeves J, Chawla S, Markman M, et al. Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: A multicenter, double-blind, randomized parallel study. J Clin Oncol 1998;16(2):754-60.
Frakes LA, Brehm TL, Kosty MP, Miller WE, McMillan RL, Mason J, et al. An all oral antiemetic regimen for patients undergoing high-dose chemotherapy with peripheral blood stemcell transplant. Bone Marrow Transplant 1997;20(6):473-8.
Published
How to Cite
Issue
Section
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
